Ontology highlight
ABSTRACT:
SUBMITTER: Improta G
PROVIDER: S-EPMC4576895 | biostudies-literature | 2015
REPOSITORIES: biostudies-literature
Improta Giuseppina G Leone Isabella I Donia Marco M Gieri Stefania S Pelosi Giuseppe G Fraggetta Filippo F
OncoTargets and therapy 20150914
Cancer immunotherapy is now recognized to be fundamental in modern oncology, because immune system recruitment may represent a powerful and innovative strategy in cancer therapy. Pembrolizumab, a highly selective humanized monoclonal antibody directly blocking the interaction between programmed cell death-1 expressed by tumor-associated T-cells and its ligand programmed cell death-L1 present on tumor and stromal cells, was recently approved by US Food and Drug Administration for the treatment of ...[more]